



## Acumen Pharmaceuticals to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference

May 13, 2024

CHARLOTTESVILLE, Va., May 13, 2024 (GLOBE NEWSWIRE) -- [Acumen Pharmaceuticals, Inc.](#) (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers for the treatment of Alzheimer's disease, announced today that management will participate in a fireside chat at the H.C. Wainwright 2<sup>nd</sup> Annual BioConnect Conference on Monday, May 20, 2024, at 12:30 p.m. ET.

The live webcast may be accessed under the Investors tab on [www.acumenpharm.com](http://www.acumenpharm.com) and will be archived for 90 days.

### About Acumen Pharmaceuticals, Inc.

Acumen, headquartered in Charlottesville, VA, with additional offices in Indianapolis, IN and Newton, MA, is a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers (A $\beta$ Os) for the treatment of Alzheimer's disease (AD). Acumen's scientific founders pioneered research on A $\beta$ Os, which a growing body of evidence indicates are early and persistent triggers of Alzheimer's disease pathology. Acumen is currently focused on advancing its investigational product candidate, sabirnetug (ACU193), a humanized monoclonal antibody that selectively targets toxic soluble A $\beta$ Os, following positive results in INTERCEPT-AD, a Phase 1 clinical trial involving early Alzheimer's disease patients. For more information, visit [www.acumenpharm.com](http://www.acumenpharm.com).

### Investors:

Alex Braun

[abraun@acumenpharm.com](mailto:abraun@acumenpharm.com)

### Media:

[AcumenPR@westwicke.com](mailto:AcumenPR@westwicke.com)